Literature DB >> 28477697

Decreased baroreflex sensitivity in Parkinson's disease is associated with orthostatic hypotension.

Andrej Blaho1, Stanislav Šutovský2, Peter Valkovič3, Pavel Šiarnik4, Marek Sýkora5, Peter Turčáni4.   

Abstract

BACKGROUND: Autonomic dysfunction is a substantial part of extrapyramidal diseases, including Parkinson's disease (PD). Baroreflex is an important determinant of short-term blood pressure regulation and cardiovascular variability. Impaired baroreflex sensitivity (BRS) in PD has been a subject of investigation in several studies, however the relationship between BRS and orthostatic hypotension (OH) is still poorly understood.
OBJECTIVE: To compare the BRS of Parkinson's disease patients with those of an age-matched control population, and to determine BRS association with blood pressure, orthostatic hypotension and antiparkinson treatment. PATIENTS AND METHODS: The study included 52 patients with Parkinson's disease and 52 controls. We assessed autonomic dysfunction with a Finometer device using the method of spontaneous fluctuations of blood pressure (BP) and the R-R interval in time domain, expressed as baroreflex sensitivity. Supine and standing blood pressure were measured under standard conditions.
RESULTS: BRS values were significantly lower in the PD group as compared to the control group: 4.0±2.0 vs. 6.4±3.8ms/mmHg (p=0.001). We determined a significant correlation between decreased BRS values and increased systolic BP (p=0.003) as well as between decreased BRS values and orthostatic hypotension (OH), in the PD group (p=0.048). Moreover, patients with PD and OH had significantly lower BRS as compared with patients with PD without OH (3.2±2 versus 4.5±2, p=0.045). We also determined that BRS values were significantly lower in the PD population treated with LDOPA+COMTI as compared to the LDOPA+COMTI untreated patients (3.0±1.5 vs. 4.8±2.0, p<0.001).
CONCLUSION: BRS was significantly lower in the PD group, supine hypertension and orthostatic hypotension was strongly associated with low BRS. We determined for the first time that orthostatic hypotension strongly correlates with decreased baroreflex sensitivity in PD patients. Moreover, orthostatic hypotension was associated with low BRS not only qualitatively but also quantitatively. We also revealed a strong association between LDOPA+COMTI therapy and decreased BRS in the literature for the first time.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autonomic dysfunction; Baroreflex sensitivity; Orthostatic hypotension; Parkinson's disease

Mesh:

Year:  2017        PMID: 28477697     DOI: 10.1016/j.jns.2017.03.044

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  4 in total

1.  Levodopa-Carbidopa Intestinal Gel Improves Symptoms of Orthostatic Hypotension in Patients with Parkinson's Disease-Prospective Pilot Interventional Study.

Authors:  Simona Stanková; Igor Straka; Zuzana Košutzká; Peter Valkovič; Michal Minár
Journal:  J Pers Med       Date:  2022-04-29

2.  Cardiovascular autonomic responses in patients with Parkinson disease to pedunculopontine deep brain stimulation.

Authors:  Jonathan A Hyam; Holly A Roy; Yongzhi Huang; Sean Martin; Shouyan Wang; Jodi Rippey; Terry J Coyne; Ian Stewart; Graham Kerr; Peter Silburn; David J Paterson; Tipu Z Aziz; Alexander L Green
Journal:  Clin Auton Res       Date:  2019-09-06       Impact factor: 4.435

Review 3.  Altered cardiorespiratory regulation during exercise in patients with Parkinson's disease: A challenging non-motor feature.

Authors:  Jeann L Sabino-Carvalho; Lauro C Vianna
Journal:  SAGE Open Med       Date:  2020-05-06

4.  Effectiveness of Different Methods for Baroreflex Sensitivity Assessment in Determining the Severity of Cardiovascular Autonomic Neuropathy in Patients With Parkinson's Disease.

Authors:  Chih-Cheng Huang; Yun-Ru Lai; Chia-Yi Lien; Ben-Chung Cheng; Chia-Te Kung; Yi-Fang Chiang; Cheng-Hsien Lu
Journal:  Front Neurosci       Date:  2022-02-25       Impact factor: 4.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.